Bendamustin (B) and rituximab (R) in the treatment of relapsed indolent CD 20+ non-Hodgkin-lymphoma - A phase II study of The East German Study Group of haematology and oncology (OSHO # 072)

被引：0
|
作者：
Lakner, V. [1 ]
Eschenburg, H. [1 ]
Aldaoud, A. [1 ]
Uhlig, J. [1 ]
机构：
[1] Praxis, Leipzig, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：209 / 210
页数：2
相关论文
共 50 条
  • [41] Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide plus Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Lansigan, Frederick
    Andorsky, David Jacob
    Coleman, Morton
    Yacoub, Abdulraheem
    Melear, Jason
    Fanning, Suzanne
    Kolibaba, Kathryn S.
    Reynolds, Christopher M.
    Nowakowski, Grzegorz S.
    Gharibo, Mecide
    Ahn, Jung Ryun
    Li, Ju
    Rummel, Mathias J.
    Sharman, Jeff P.
    BLOOD, 2021, 138
  • [42] Phase II study of oral Fludarabine (FAMP) in combination with rituximab in indolent B-cell non-hodgkin lymphoma (B-NHL)
    Ishizawa, Kenichi
    Tobinai, Kensei
    Ogura, Michinori
    Itoh, Kuniaki
    Aorishima, Yasuo
    Ando, Kiyoshi
    Yamamoto, Joji
    Watanabe, Takashi
    Uchida, Toshiki
    Nakata, Masanobu
    Hayashi, Masaki
    Hotta, Tomomitsu
    BLOOD, 2007, 110 (11) : 387A - 387A
  • [43] Treatment of mantle cell lymphoma (MCL) by allogeneic stem cell transplantation - results from the prospective trials #060 and #074 of the East German Study Group for Haematology and Oncology (OSHO)
    Krueger, W. H.
    Basara, N.
    Hirt, C.
    Niederwieser, D.
    Behre, G.
    Grobe, N.
    Sayer, H.
    Maschmeyer, G.
    Haas, A.
    Fischer, T.
    Kiehl, M.
    Busemann, C.
    Doelken, G.
    ONKOLOGIE, 2011, 34 : 70 - 72
  • [44] Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden
    Igarashi, Tadahiko
    Ogura, Michinori
    Itoh, Kuniaki
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Kuroda, Yoshiaki
    Yamamoto, Kazuhito
    Uike, Naokuni
    Tomita, Akihiro
    Nagai, Hirokazu
    Kurosawa, Mitsutoshi
    Mori, Shigeo
    Nawano, Shigeru
    Terauchi, Takashi
    Ohashi, Yasuo
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (06) : 700 - 708
  • [45] Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden
    Tadahiko Igarashi
    Michinori Ogura
    Kuniaki Itoh
    Masafumi Taniwaki
    Kiyoshi Ando
    Yoshiaki Kuroda
    Kazuhito Yamamoto
    Naokuni Uike
    Akihiro Tomita
    Hirokazu Nagai
    Mitsutoshi Kurosawa
    Shigeo Mori
    Shigeru Nawano
    Takashi Terauchi
    Yasuo Ohashi
    Kensei Tobinai
    International Journal of Hematology, 2016, 104 : 700 - 708
  • [46] Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study
    Evens, Andrew M.
    Smith, Mitchell R.
    Lossos, Izidore S.
    Helenowski, Irene
    Millenson, Michael
    Winter, Jane N.
    Rosen, Steve T.
    Gordon, Leo I.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (04) : 514 - 520
  • [47] Rituximab in relapsed lymphocyte predominant Hodgkin's disease (LPHD). Long-term results of a phase-II study from the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz, H
    Trelle, S
    Reiser, M
    Sieber, M
    Diehl, V
    Engert, A
    BLOOD, 2005, 106 (11) : 433A - 433A
  • [48] High anti-lymphoma activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in rituximab pretreated relapsed or refractory indolent lymphomas. A multicentre phase II study of the german low grade lymphoma study group (GLSG).
    Weide, Rudolf
    Hess, Georg
    Koeppler, Hubert
    Heymanns, Jochen
    Thomalla, Joerg
    Aldaoud, Ali
    Losem, Christoph
    Schmitz, Stefan
    Haak, Ursula
    Huber, Christoph
    Unterhalt, Michael
    Hiddemann, Wolfgang
    Dreyling, Martin
    BLOOD, 2006, 108 (11) : 702A - 703A
  • [49] Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide plus Rituximab (R2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Lansigan, Frederick
    Andorsky, David Jacob
    Coleman, Morton
    Yacoub, Abdulraheem
    Melear, Jason M.
    Fanning, Suzanne R.
    Kolibaba, Kathryn S.
    Reynolds, Chris
    Nowakowski, Grzegorz S.
    Gharibo, Mecide
    Ahn, Jung Ryun
    Li, Ju
    Rummel, Mathias J.
    Sharman, Jeff P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 104 - 105
  • [50] MAGNIFY Phase 3b Study of Lenalidomide plus Rituximab (R2) Followed by Maintenance in Relapsed/ Refractory Indolent Non-Hodgkin Lymphoma: Complete Induction Phase Analysis
    Lansigan, Frederick
    Andorsky, David Jacob
    Coleman, Morton
    Yacoub, Abdulraheem
    Melear, Jason M.
    Fanning, Suzanne R.
    Kolibaba, Kathryn S.
    Reynolds, Chris
    Nowakowski, Grzegorz S.
    Gharibo, Mecide
    Ahn, Jung Ryun
    Li, Ju
    Rummel, Mathias J.
    Sharman, Jeff P.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S384 - S384
12345